Publications

Pharmaceuticals (Basel, Switzerland)

Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs.

13-07-2022

Cancer chemotherapy and pharmacology

Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies.

01-07-2022

Clinical pharmacology and therapeutics

Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study.

01-07-2022

Journal of pharmaceutical and biomedical analysis

A highly sensitive bioanalytical method for the quantification of vinblastine, vincristine, vinorelbine and 4-O-deacetylvinorelbine in human plasma using LC-MS/MS.

05-06-2022

Cancer chemotherapy and pharmacology

Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.

01-06-2022

Cancer chemotherapy and pharmacology

Is age just a number? A population pharmacokinetic study of gemcitabine.

01-05-2022

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Optimized sample pre-treatment procedure for the simultaneous UPLC-MS/MS quantification of ipilimumab, nivolumab, and pembrolizumab in human serum.

30-04-2022

Pharmacological research

ABCB1 limits brain exposure of the KRAS^G12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability.

01-04-2022

Pharmacological research

ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites.

01-04-2022

Pharmaceutical research

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib.

01-04-2022

Drug metabolism and disposition: the biological fate of chemicals

Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients.

01-04-2022

Frontiers in pharmacology

Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites.

22-03-2022

Journal of pharmaceutical sciences

Population Pharmacokinetic Modelling to Support the Evaluation of Preclinical Pharmacokinetic Experiments with Lorlatinib.

01-02-2022

Clinical pharmacology and therapeutics

Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer.

01-02-2022

BMC cancer

The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.

25-01-2022

Journal of pharmaceutical and biomedical analysis

Development and validation of an HPLC-MS/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue.

05-01-2022

Journal of pharmaceutical and biomedical analysis

Development and validation of an LC-MS/MS assay for the quantification of cintirorgon (LYC-55716) in mouse plasma and tissue homogenates.

05-01-2022

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinib.

01-01-2022

Drugs

Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer.

01-01-2022

International journal of antimicrobial agents

An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis.

01-01-2022

Targeted oncology

Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice.

01-01-2022

Clinical cancer research : an official journal of the American Association for Cancer Research

Precision Dosing of Targeted Therapies Is Ready for Prime Time.

15-12-2021

Molecular pharmaceutics

P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib.

06-12-2021

Clinical pharmacokinetics

Correction to: Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review.

01-11-2021

Clinical pharmacology and therapeutics

Response to "Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence".

01-11-2021

Pharmaceuticals (Basel, Switzerland)

P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO).

27-10-2021

Journal of pharmaceutical and biomedical analysis

Quantification of anti-SARS-CoV-2 antibodies in human serum with LC-QTOF-MS.

25-10-2021

Pharmaceutics

ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability.

21-10-2021

NPJ breast cancer

IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women.

20-10-2021

Drug and alcohol dependence

The suitability of oral diacetylmorphine in treatment-refractory patients with heroin dependence: A scoping review.

01-10-2021

Pharmacological research

ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib.

01-10-2021

Frontiers in pharmacology

A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs.

17-09-2021

Journal of pharmaceutical and biomedical analysis

Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLC-MS/MS.

05-09-2021

EJNMMI research

A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of ⁶⁸Ga-DOTATATE in patients without neuroendocrine tumors.

16-08-2021

Journal for immunotherapy of cancer

HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial.

01-08-2021